Molecular Basis of Chronic Myeloproliferative Disorders

  • Petro E. Petrides
  • Heike L. Pahl
Conference proceedings

Table of contents

  1. Front Matter
    Pages I-XII
  2. Basics

    1. Front Matter
      Pages 1-1
    2. Jürgen Thiele, Hans Kvasnicka
      Pages 15-27
    3. Anthony J. Bench, Brian J. Petro Huntly, Anthony R. Green
      Pages 28-37
  3. Polycythemia Vera

  4. Essential Thrombocythemia

    1. Front Matter
      Pages 91-91
    2. Radek C. Skoda, Adrian Wiestner, Nico Ghilardi, Stephan Padosch
      Pages 99-105
    3. Petro E. Petrides, Britta Seidemann, Brigitte Wittmann-Liebold
      Pages 106-116
    4. Rosemary E. Gale
      Pages 117-123
  5. Chronic Idiopathic Myelofibrosis

    1. Front Matter
      Pages 131-131
    2. Jiandie Lin, Daniel I. H. Linzer
      Pages 133-138
    3. Marie-Caroline Le Bousse-Kerdilès, Marie-Claire Martyré
      Pages 139-146
    4. Pedro Gascon, Pranela Rameshwar
      Pages 147-155
    5. Alain Schmitt, Arnaud Drouin, Jean-Marc Massé, Josette Guichard, Hedia Shagraoui, Elisabeth M. Cramer
      Pages 156-165
  6. Mastocytosis

    1. Front Matter
      Pages 167-167
    2. Frédéric Féger, Olivier Hermine, Jean-Jacques Guillosson, Michel Arock
      Pages 169-179
    3. Dagmar Ludolph-Hauser, Bernhard Przybilla, Christian Petro Sommerhoff
      Pages 180-185
  7. Hypereosinophilic Syndrome

    1. Front Matter
      Pages 187-187
    2. Amy D. Klion, John D. Rioux, Melissa Law, Thomas B. Nutman
      Pages 189-194
    3. Szu-Hee Lee, Hsiao-Wen Chang
      Pages 201-206
    4. Florence Roufosse, L. Schandené, A. de Lavareille, E. Cogan, M. Goldman
      Pages 207-214
  8. Back Matter
    Pages 215-218

About these proceedings


Since the first description of Philadelphia chromosome-negative chronic myeloproliferative disorders more than 100 years ago, the diagnosis and therapy of these conditions have been based primarily on clinical experience and judgement. Until recently very little was known about the molecular basis of these diseases. In order to spark research in this area basic scientists and clinicians from various parts of the world have contributed to this volume, the first of its kind to put together the current knowledge. The book deals with the new WHO classification of these disorders, novel aspects of diagnostic pathology, the search for disease-relevant genes utilizing molecular biology and proteomic techniques, the description of the roles of PVR-1 and VHL genes for polycythemias and the discovery of the gene mutation responsible for the idiopathic hypereosinophilic syndrome. A chapter on anagrelide, an important novel drug for the treatment of primary thrombocythemia, is included.


classification growth factor idiopathic hypereosinophilic syndrome idiopathic myelofibrosis mastocytosis polycythemia vera polycythemias primary thrombocythemia prolactin thrombopoietin

Editors and affiliations

  • Petro E. Petrides
    • 1
    • 2
  • Heike L. Pahl
    • 3
  1. 1.Hematology Oncology CenterMunichGermany
  2. 2.University of Munich Medical SchoolMunichGermany
  3. 3.Department of Experimental AnaesthesiologyUniversity Hospital Freiburg, Center for Clinical ResearchFreiburgGermany

Bibliographic information

  • DOI
  • Copyright Information Springer-Verlag Berlin Heidelberg 2004
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-62271-7
  • Online ISBN 978-3-642-18738-4
  • Buy this book on publisher's site